Interpace Biosciences, Inc. Common Stock
IDXG
IDXG was delisted on the 24th of February, 2021.
26 hedge funds and large institutions have $11.2M invested in Interpace Biosciences, Inc. Common Stock in 2014 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 5 closing their positions.
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
4% less funds holding
Funds holding: 27 → 26 (-1)
35% less capital invested
Capital invested by funds: $17.4M → $11.2M (-$6.15M)
44% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 9
Top Buyers
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $2 | – | – | – |
|
|
KCM
27
Kennedy Capital Management
St Louis,
Missouri
| – | -$615K | -2,562 | Closed |
|
|
MAP
28
Managed Asset Portfolios
Rochester,
Michigan
| – | -$24K | -100 | Closed |
|
|
BA
29
BlackRock Advisors
Wilmington,
Delaware
| – | -$6K | -25 | Closed |
|
|
MA
30
MUFG Americas
New York
| – | -$2K | -7 | Closed |
|
|
TRCT
31
Tower Research Capital (TRC)
New York
| – | -$1K | -4 | Closed |
|
IDXG Hedge Fund Activity: Q4 2014 in Review
26 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q4 2014, worth a combined $11.2M — down 35% from $17.4M a quarter earlier.
Fund positioning in IDXG was balanced in Q4 2014: 5 funds opened new positions, 5 closed out, 5 added to existing stakes and 9 trimmed.
The largest buyer was Ancora Advisors, opening a new position worth an estimated $276K. The largest seller was Royce & Associates, cutting an estimated $1.01M.
- 26 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q4 2014, down from 27 in Q3 2014.
- Funds reported $11.2M of Interpace Biosciences, Inc. Common Stock stock for Q4 2014, down 35% quarter-over-quarter.
- 5 funds opened new Interpace Biosciences, Inc. Common Stock positions in Q4 2014 and 5 closed out, a net change of 0 holders.
- The largest Interpace Biosciences, Inc. Common Stock buyer in Q4 2014 was Ancora Advisors, an estimated $276K added.
- The largest Interpace Biosciences, Inc. Common Stock seller in Q4 2014 was Royce & Associates, an estimated $1.01M sold.
Based on aggregated 13F filings for Q4 2014.